All News
ICYMI: Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA
The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to at-risk rheumatoid arthritis patients. These findings are in addition to the thrombotic risks (added to the label), potential risks including blood clots in the lungs and death.
Read Article
ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate
The American College of Rheumatology (ACR) has issued new guidelines on the treatment of rheumatoid arthritis, addressing questions about initial treatment with methotrexate and minimizing reliance on glucocorticoids.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Stands Against Insurer Mandated Infusion Locations
The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid
Read Article
Links:
Pain Persists in RA, Even Without Inflammation
One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
Read Article
Better Outcomes with Modern T2T in Pregnancy
With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.
Read Article
Links:
Progression from Psoriasis to Psoriatic Arthritis
The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).
Read Article
FINCH 1 Trial Filgotinib in Rheumatoid Arthritis
The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).
Read Article
Links:
Links:
Links: